MoonLake Immunotherapeutics (MLTX)
Market Cap | 2.52B |
Revenue (ttm) | n/a |
Net Income (ttm) | -45.84M |
Shares Out | 62.87M |
EPS (ttm) | -0.73 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 379,417 |
Open | 41.60 |
Previous Close | 41.80 |
Day's Range | 40.00 - 42.19 |
52-Week Range | 35.11 - 64.98 |
Beta | 1.25 |
Analysts | Strong Buy |
Price Target | 76.33 (+90.11%) |
Earnings Date | Aug 8, 2024 |
About MLTX
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for MLTX stock is "Strong Buy." The 12-month stock price forecast is $76.33, which is an increase of 90.11% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/m/r/press4-2434520.jpg)
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody ® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
![](https://cdn.snapi.dev/images/v1/g/i/press12-2414462.jpg)
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3 program...
![](https://cdn.snapi.dev/images/v1/m/8/press18-2364765.jpg)
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
MoonLake Immunotherapeutics inks three-year technology partnership with Komodo Health to advance research on inflammatory skin and joint conditions
![](https://cdn.snapi.dev/images/v1/e/j/press14-2364783.jpg)
MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
SAN FRANCISCO & ZUG, Switzerland--(BUSINESS WIRE)--MoonLake Immunotherapeutics (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammat...
![](https://cdn.snapi.dev/images/v1/g/j/press10-2316942.jpg)
MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
MoonLake announces significant improvements with Nanobody ® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
![](https://cdn.snapi.dev/images/v1/a/c/conf13-2306050.jpg)
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
MoonLake Immunotherapeutics to present MIRA trial data of Nanobody ® sonelokimab in hidradenitis suppurativa as a late breaker at the AAD Annual Meeting 2024
![](https://cdn.snapi.dev/images/v1/q/y/press8-2300900.jpg)
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
MoonLake Immunotherapeutics Reports Full Year 2023 Financial Results, Recent Business Highlights and Announces an R&D Day on March 10
![](https://cdn.snapi.dev/images/v1/v/k/press16-2293252.jpg)
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody ® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
![](https://cdn.snapi.dev/images/v1/k/s/press9-2156644.jpg)
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Third Quarter 2023 Financial Results and Provides a Business Update Announced positive full 24-week data from the global Phase 2 MIRA clinical trial, establishing t...
![](https://cdn.snapi.dev/images/v1/8/q/press12-2140778.jpg)
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody ® sonelokimab in active psoriatic arthritis
![](https://cdn.snapi.dev/images/v1/v/f/press11-2103741.jpg)
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody® sonelokimab as a highly promising and differentiated therapeutic solution for Hidradenitis Suppurativa
MoonLake Immunotherapeutics announces the full dataset from its 24-week MIRA clinical trial, establishing the Nanobody ® sonelokimab as a highly promising and differentiated therapeutic solution for H...
![](https://cdn.snapi.dev/images/v1/g/l/press11-2098926.jpg)
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody ® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology C...
![](https://cdn.snapi.dev/images/v1/u/w/press9-2089065.jpg)
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake's Nanobody ® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatolog...
![](https://cdn.snapi.dev/images/v1/z/r/press12-2050865.jpg)
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
MoonLake Immunotherapeutics to ho st a Capital Markets Day on Monday , September 11
![](https://cdn.snapi.dev/images/v1/e/q/press5-2016719.jpg)
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
ZUG, Switzerland, August 10, 2023 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake” or the “Company”), a clinical-stage biotechnology company focused on creating next-level therapies for inflamm...
![](https://cdn.snapi.dev/images/v1/l/h/press6-1986075.jpg)
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
![](https://cdn.snapi.dev/images/v1/b/o/wadgsc6jsbjozb4jiam6inncfy-1972517.jpg)
Exclusive: MoonLake Immunotherapeutics explores sale-sources
MoonLake Immunotherapeutics , a developer of an antibody-derived treatment for inflammatory skin conditions, is exploring a sale, according to people familiar with the matter.
![](https://cdn.snapi.dev/images/v1/y/0/press16-1950847.jpg)
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
MoonLake Immunotherapeutics Announces Pricin g of $ 40 0 Million Upsized Public Offering of Class A Ordinary Shares
![](https://cdn.snapi.dev/images/v1/r/b/press12-1948476.jpg)
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
![](https://cdn.snapi.dev/images/v1/p/l/press17-1946959.jpg)
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
MoonLake Immunot herapeutics achieves landmark milestone with positive Phase 2 results for Nanobody ® sonelokimab in hidradenitis suppurativa
![](https://cdn.snapi.dev/images/v1/i/i/press3-1887229.jpg)
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted the differentiating features of sonelokimab and st...
![](https://cdn.snapi.dev/images/v1/i/e/press6-1867812.jpg)
MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply
ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, toda...
![](https://cdn.snapi.dev/images/v1/h/m/press14-1843392.jpg)
MoonLake Immunotherapeutics to host Capital Markets Day in New York and virtually today
ZUG, Switzerland, April 19, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases,...
![](https://cdn.snapi.dev/images/v1/d/t/press20-1803806.jpg)
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
MoonLake Immunotherapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides a Business Update
![](https://cdn.snapi.dev/images/v1/m/z/press7-1735299.jpg)
MoonLake Immunotherapeutics completes patient enrollment and randomization ahead of schedule in a Phase 2 trial of the Nanobody® sonelokimab in moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics com pletes patient enrol l ment and randomization ahead of schedule in a Phase 2 trial of the Nanobody ® sonelokimab in moderate-to-severe hidradenitis suppurativa